Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition

Abstract

Resistance to the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib has been attributed solely to mutations in BTK and related pathway molecules. Using whole-exome and deep-targeted sequencing, we dissect evolution of ibrutinib resistance in serial samples from five chronic lymphocytic leukaemia patients. In two patients, we detect BTK-C481S mutation or… (More)
DOI: 10.1038/ncomms11589

6 Figures and Tables

Topics

  • Presentations referencing similar topics